(Q36203250)

12 August 2017

1 reference

title

Skeletal and nonskeletal effects of raloxifene (English)

1 reference

12 August 2017

Oscar Gluck

1

1 reference

12 August 2017

Michael Maricic

series ordinal

2

1 reference

12 August 2017

language of work or name

1 reference

1 December 2003

1 reference

Current osteoporosis reports

12 August 2017

published in

1 reference

12 August 2017

volume

1

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

123-128

1 reference

Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02686917

Vertebral fracture assessment using a semiquantitative technique.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02686917

Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.

21 January 2018

1 reference

12 December 2020

Breast cancer chemoprevention: current status and future directions

1 reference

12 December 2020

Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women

1 reference

12 December 2020

The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

1 reference

12 December 2020

Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women

1 reference

12 December 2020

Cognitive function in postmenopausal women treated with raloxifene

1 reference

12 December 2020

Comparative analyses of mechanistic differences among antiestrogens

1 reference

12 December 2020

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

12 December 2020

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

12 December 2020

ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

12 December 2020

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

12 December 2020

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Selective estrogen receptor modulators: structure, function, and clinical use.

1 reference

12 December 2020

The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study

1 reference

12 December 2020

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Molecular determinants for the tissue specificity of SERMs

1 reference

12 December 2020

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

1 reference

12 December 2020

Updated data on proximal femur bone mineral levels of US adults

1 reference

12 December 2020

Raloxifene effect on frequency of surgery for pelvic floor relaxation

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02686917

1 reference

12 August 2017

1 reference